TY - JOUR
T1 - RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma
AU - Kurashige, J.
AU - Watanabe, M.
AU - Iwatsuki, M.
AU - Kinoshita, K.
AU - Saito, S.
AU - Nagai, Y.
AU - Ishimoto, T.
AU - Baba, Y.
AU - Mimori, K.
AU - Baba, H.
N1 - Funding Information:
We thank Mrs Y Taniguchi, Mr Y Miyake and Ms N Yokoyama for their excellent technical assistance. This work was supported in part by the following grants and foundations: Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (grant number 23791550), Takeda Science Foundation 2010, Okukubo Memorial Fund for Medical Research in Kumamoto University School of Medicine 2010, Uehara Memorial Foundation 2010 and the Yokoyama Foundation for Clinical Pharmacology 2011.
PY - 2012/10/9
Y1 - 2012/10/9
N2 - Background: Neoadjuvant chemotherapy - often using docetaxel in various combinatorial regimens - is a standard treatment choice for advanced oesophageal squamous cell carcinoma (ESCC) in Japan. However, no useful markers exist that predict docetaxels effects on ESCC. Ribophorin II (RPN2) silencing, which reduces glycosylation of P-glycoproteins and decreases membrane localisation, promotes docetaxel-dependent apoptosis. We investigated whether RPN2 expression in ESCC biopsy specimens could be a predictive biomarker in docetaxel-based neoadjuvant chemotherapy. Methods: We evaluated RPN2 expression immunohistochemically in biopsy specimens from 79 patients with node-positive ESCC, who received docetaxel-based adjuvant chemotherapy, and compared clinical and pathological responses between the RPN2-positive and RPN2-negative groups. We also studied susceptibility of RPN2-suppressed ESCC cells to docetaxel. Results: The RPN2-negative group had better clinical and pathological responses to docetaxel than the RPN2-positive group. We also found RPN2 suppression to alter docetaxel susceptibility in vitro. Conclusion: Expression of RPN2 in biopsy specimens could be a useful predictive marker for response to docetaxel-based neoadjuvant chemotherapy in ESCC.
AB - Background: Neoadjuvant chemotherapy - often using docetaxel in various combinatorial regimens - is a standard treatment choice for advanced oesophageal squamous cell carcinoma (ESCC) in Japan. However, no useful markers exist that predict docetaxels effects on ESCC. Ribophorin II (RPN2) silencing, which reduces glycosylation of P-glycoproteins and decreases membrane localisation, promotes docetaxel-dependent apoptosis. We investigated whether RPN2 expression in ESCC biopsy specimens could be a predictive biomarker in docetaxel-based neoadjuvant chemotherapy. Methods: We evaluated RPN2 expression immunohistochemically in biopsy specimens from 79 patients with node-positive ESCC, who received docetaxel-based adjuvant chemotherapy, and compared clinical and pathological responses between the RPN2-positive and RPN2-negative groups. We also studied susceptibility of RPN2-suppressed ESCC cells to docetaxel. Results: The RPN2-negative group had better clinical and pathological responses to docetaxel than the RPN2-positive group. We also found RPN2 suppression to alter docetaxel susceptibility in vitro. Conclusion: Expression of RPN2 in biopsy specimens could be a useful predictive marker for response to docetaxel-based neoadjuvant chemotherapy in ESCC.
UR - http://www.scopus.com/inward/record.url?scp=84867405542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867405542&partnerID=8YFLogxK
U2 - 10.1038/bjc.2012.396
DO - 10.1038/bjc.2012.396
M3 - Article
C2 - 22955852
AN - SCOPUS:84867405542
SN - 0007-0920
VL - 107
SP - 1233
EP - 1238
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 8
ER -
